RE:RE:Why low-cost ketamine is still inaccessible to many...For sure...thats how I see things here for PHRM. Short and long term, this company will be huge in valuation. Time will only tell of coarse. Thats why I'm in and accumulating a very large position. My view only, and others need to do their own DD and come to their own conclusion....FDA approval is inevitable, and as such will attract investors, and big Pharma.
Key Features:
- Very Low share count outstanding float, 88 million shares
- CEO has a huge position of close to 20%, holding over 15.5 Million shares
- Large pipeline of products in near term trials.."PharmaPatch" and ALS..Parkinsons..Rett Syn..
- Sairiyo Spin-out with their Cepharantine oral reformulated drug for oncology & infectious diseases
- Positive cash balance over $4mm with NO DEBT..
This is WHY I'm in...Todays share price of .22 cents, reflects a measely market cap of $19mm, and once FDA approved will command a much higher valuation ....You determine your own price target..I have mine already formulated with an exit strategy....Good Luck to all holding and buying..